SPH-4336

N/A

Report date: 2025/11/03 16:01:23
NME

Base Information

Drug NameSPH-4336
Drug Alias NameSPH-4336I-022I022
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Pharmaceuticals Holding Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSph (Benxi) North Pharmaceutical Co LtdShanghai Pharmaceuticals Holding Co Ltd
Inactive CompaniesShanghai Pharma Biotherapeutics USA Inc
Active IndicationsMetastatic breast cancerSolid tumoursBreast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A